Navigation Links
Avanir Pharmaceuticals to Present Data at MS-Focused ECTRIMS Annual Meeting
Date:10/18/2011

ALISO VIEJO, Calif., Oct. 18, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands. ECTRIMS is considered the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis.

Following are details about the data presentation:

Title: Safety and Tolerability of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Multiple Sclerosis during a 12-week Double-Blind, Placebo-Controlled Study
Program Number: P564 (Poster Presentation)
Presentation Date/Time: Thursday, October 20, 2011 15:30 CET

About PBA

Patients suffering from existing neurological disease or brain injury may also suffer the added burden of pseudobulbar affect, or PBA. PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. PBA outbursts result from a "short circuit" in the brain caused by another neurologic condition--such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, or traumatic brain injury. PBA can have a debilitating impact on the lives of patients, caregivers and loved ones. For more information about PBA, please visit www.PBAinfo.org.

About NUEDEXTA

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AVANIR to Present at the Wedbush Life Sciences Conference
2. AVANIR to Present at the Canaccord Genuity Growth Conference
3. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Avanir Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
11. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Midwest Biotech Leaders Featured On BioSpace Map 2
... To validate any RNAi experiment, target mRNA , ... using a positive control siRNA that is known to be effective, , ... , Validation is also necessary ... effectiveness and potency of any siRNA sequence. Finally, , ...
... Microarrays , ... engineered to maximize yields of full-length cDNA , ... 100 ng of input RNA in a single round for GeneChip , ... cRNA synthesis powered by , MEGAscript, the best ...
... Total RNA Isolation from Formalin Fixed Paraffin Embedded (FFPE) Tissues , ... Phenol-free isolation of total RNA from , FFPE tissues , ... href="http://www.ambiondx.com/products/optimum/index.html">Optimum , ... and rapid protocol , for ...
Cached Biology Technology:Confirming RNAi Effects Is Now Easier Than Ever 2Confirming RNAi Effects Is Now Easier Than Ever 3Confirming RNAi Effects Is Now Easier Than Ever 4Confirming RNAi Effects Is Now Easier Than Ever 5Improving RNA Amplification 2Improving RNA Amplification 3Improving RNA Amplification 4Improving RNA Amplification 5Improving RNA Amplification 6Improving RNA Amplification 7Improving RNA Amplification 8Improving RNA Amplification 9Improving RNA Amplification 10Improving RNA Amplification 11Improving RNA Amplification 12Improving RNA Amplification 13Improving RNA Amplification 14Optimum FFPE RNA Isolation Kit 2Optimum FFPE RNA Isolation Kit 3Optimum FFPE RNA Isolation Kit 4
(Date:7/31/2014)... protected 100 percent of animal models against the highly ... causes an intestinal disease that kills approximately 30,000 Americans ... Infection and Immunity . , In the ... against the purified toxins produced by C. difficile ... a laboratory model that mimics the human disease, after ...
(Date:7/31/2014)... better identify and treat those with fibromuscular dysplasia (FMD). ... sized arteries in the body, which can restrict blood flow ... new report appearing in August 2014 issue of ... FMD may not be limited to the arteries as currently ... bones and joints, as well as evidence that inflammation may ...
(Date:7/31/2014)... they are an iconic symbol of tropical resorts ... landscape. Some, like Hawaii,s State Flower- Hibiscus ... relatively few botanists and Hawaiian conservation workers, however, ... related group of plants known as Hibiscadelphus ... Hibiscus species are in fact highly endangered. Until ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2Brother of Hibiscus is found alive and well on Maui 2
... developed a slow-release anesthetic drug-delivery system that could ... surgery, and may also have a large impact ... used specially designed fat-based particles called liposomes to ... local anesthesia in rats without apparent toxicity to ...
... Climate change will cause some of Australia,s potential weeds to ... by scientists at CSIRO,s Climate Adaptation Flagship. Weeds cost ... or lost production and cause serious damage to the environment. ... GREENHOUSE 09 conference on climate change, CSIRO researcher, Dr John ...
... Fast food and soft drinks may be making children fatter ... tackling childhood obesity, by reducing children,s consumption of unhealthy food ... also actively seek to keep children happy in other ways, ... Professor Rodolfo Nayga from the University of Arkansas in the ...
Cached Biology News:Long-lasting nerve block could change pain management 2Climate change may wake up 'sleeper' weeds 2Eat, drink and be merry? 2
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: